Co., Inc. (NYSE: MRK) has initiated a pivotal Phase 3 clinical trial, waveLINE-010, to evaluate the efficacy of its investigational drug zilovertamab vedotin in treating patients with previously ...
Paul Nghiem, MD, PhD, and the Nghiem Lab have championed innovations in MCC treatment, delivering new treatment options, ...
The Damon Runyon Cancer Research Foundation’s innovation grants support high-risk, high reward ideas in cancer research.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback